Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Mayo Clinic
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05557877
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) patients with benign breast disease planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration, Ultrasound-Guided Biopsy
Benign Breast Neoplasm, Breast Carcinoma, Breast Fibrocystic Change
Kathryn J. Ruddy, M.D., Clinical Trials Referral Office, Barbara A. Pockaj, M.D.

See list of participating sites